Amgenvs.Moderna
AMGN vs MRNA · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Amgen is about 9.0× larger than Moderna by market cap; year to date, Moderna leads (+371.0% vs +35.6%).
Side by side
| AMGN | MRNA | |
|---|---|---|
| Market cap | $226B | $25.2B |
| Price | $442.24 | $158.83 |
| Today | −0.4% | +14.4% |
| Return YTD | +35.6% | +371.0% |
| Return 1Y | +51.1% | +412.1% |
| P/E | 25.8 | — |
| P/S | 5.9 | 11.3 |
| P/B | 19.3 | 3.7 |
Data as of 2026-08-26 · updates daily after U.S. close
The two companies
AmgenAMGN
Long-established in biotech, with oncology and haematology at the centre of the portfolio, immunology beside it and a line in bone disease. MariTide is the obesity candidate in the pipeline.
Full AMGN profile →ModernaMRNA
Built on mRNA, the technology behind its covid vaccine. The pipeline pushes the same platform into further vaccines and into oncology.
Full MRNA profile →More AMGN & MRNA comparisons
Other head-to-heads in the Biotech & innovation segment.
See where AMGN and MRNA sit in the full Medicine, pharma & life science map: every segment from suppliers to end markets.Open the Life science value chain →